GlassScriptPhysician profile
Steve M Frost
NPI 1497794663
$4,270.39
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $314 · 2021: $590 · 2022: $1,290 · 2023: $758 · 2024: $39.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $813.68 | 2019-2023 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $418.11 | 2019-2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $267.99 | 2019-2023 | |
| Boston Scientific Corporation | $260.48 | 2019-2023 | Spaceoar Vue System - 10ml |
| Dendreon Pharmaceuticals LLC | $235.33 | 2019-2023 | Provenge |
| Blue Earth Diagnostics | $204.02 | 2019-2023 | |
| Abbvie INC. | $182.47 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $159.70 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $139.75 | 2021-2023 | Yonsa |
| Urogen Pharma, INC. | $124.71 | 2022 | |
| Sumitomo Pharma America, INC. | $106.74 | 2023 | Gemtesa, Orgovyx |
| Pfizer INC. | $99.25 | 2019-2022 | |
| Travere Therapeutics, INC. | $89.38 | 2019 | |
| Myovant Sciences INC. | $88.39 | 2021-2022 | |
| Urovant Sciences INC | $87.08 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Frost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.